PPARA and metabolic dysfunction-associated steatohepatitis: Bezafibrate belongs to clinically used fibrate-class PPARα agonists but does exhibit PPAR pan activities (Figure 2D(a–e)) [10] and has only been tested so far in clinical trials for anticancer drug-induced NASH [56,57].